Here are three GI companies that made headlines this week:
San Francisco-based Versant Ventures launched Jecure Therapeutics on Feb. 15, 2017. Jecure is a biotech company with a proprietary liver disease platform. To date, it has developed treatment programs for non-alcoholic steatohepatitis and fibrosis.
Japan-based Takeda acquired Cambridge, Mass.-based Ariad Pharmaceuticals for $24 per share. New York City-based law firm Faruqi & Faruqi previously investigated whether Ariad properly executed fair sale practices.
Laval, Canada-based Valeant’s move to sell $2.1 billion in assets in January 2017 positively impacted its debt pathway. Valeant can cover its August 2018 bond when it matures.
More articles on gastroenterology:
GI leader to know: Dr. Shahab Aftahi of Estrella Gastroenterology
Versant Ventures launches Jecure Therapeutics: 4 key notes
Study associates Barrett’s esophagus with early-stage GI cancers: 3 study insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.